首頁 > 市場調查報告書 > 製藥 > 癌症 > 大腸癌、黑色素細胞癌、血管增生分析

聯絡我們?

市場調查報告書

大腸癌、黑色素細胞癌、血管增生分析

Triple Analysis: Colorectal Cancer, Melanoma and Angiogenesis

出版商	BioSeeker Group AB
出版日期	2012年01月	商品編碼	177413
內容資訊	英文 3537 Pages
價格	US $ 5175 PDF by E-mail

簡介
目錄
相關商品

大腸癌、黑色素細胞癌、血管增生分析 是由出版商BioSeeker Group AB在2012年01月所出版的。這份英文市場調查報告書包含3537 Pages 價格從美金5175起跳。

簡介

本報告針對大腸癌、黑色素細胞癌相關藥物開發策略、細胞死亡機制、目的、影響分類為焦點，提供複合策略競爭基準、臨床實驗與分析計劃，目錄介紹如下。

第1章大腸癌

本報告範圍
以最佳治療結果與投資回收率為前提的大腸癌治療目標
新藥登場：開發階段分類大腸癌藥物目標策略
使用中的複合策略：複合策略分類競爭基準
臨床實驗與分析計劃
免責事項
藥物索引
企業索引
圖表

第2章黑色素細胞癌

本報告範圍
以最佳治療結果與投資回收率為前提的黑色素細胞癌治療目標
新藥登場：開發階段分類黑色素細胞癌藥物目標策略
使用中的複合策略：複合策略分類競爭基準
臨床實驗與分析計劃
免責事項
藥物索引
企業索引
圖表

第3章血管增生

本報告範圍
以最佳治療結果與投資回收率為前提的治療目標
新藥登場：開發階段分類血管增生藥物目標策略
使用中的複合策略：複合策略分類競爭基準
藥物影響與血管增生的適應癌症
臨床實驗與分析計劃
免責事項
藥物索引
企業索引
圖表

This triple analysis focuses on cancer drug development strategies in both Colorectal Cancer and Melanoma and by the mechanism/target/effect of Angiogenesis. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Key Topics Covered:

Part I: Colorectal Cancer

5.1. The Scope of this Report
6. Consider the Therapeutic Target Among Colorectal Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (210 Drug Targets)
7. Emerging New Products to Established Ones: Drug Target Strategies of Colorectal Cancer Drugs by their Highest Stage of Development (205 Drug Target Strategies and 347 Colorectal Cancer Drugs)
8. Compound Strategies at Work: Competitive Benchmarking of Colorectal Cancer Drugs by Compound Strategy (8 Compound Strategies)
9. Pipeline and Portfolio Planning: Competitive Benchmarking of the Colorectal Cancer Drug Pipeline by Investigator (182 Companies)
10. Disclaimer
11. Drug Index
12. Company Index

Figures: Includes 6 Figures
Tables: Includes 242 Tables
Total Number of Pages: 1,056

Part II: Melanoma

5.1. The Scope of this Report
6. Consider the Therapeutic Target Among Melanoma Drugs for the Highest Therapeutic Outcome and Return on Investment (170 Drug Targets)
7. Emerging New Products to Established Ones: Drug Target Strategies of Melanoma Drugs by their Highest Stage of Development (151 Drug Target Strategies and 218 Melanoma Drugs)
8. Compound Strategies at Work: Competitive Benchmarking of Melanoma Drugs by Compound Strategy (8 Compound Strategies)
9. Pipeline and Portfolio Planning: Competitive Benchmarking of the Melanoma Drug Pipeline by Investigator (138 Companies)
10. Disclaimer
11. Drug Index
12. Company Index

Figures: Includes 6 Figures
Tables: Includes 196 Tables
Total Number of Pages: 777

Part III: Angiogenesis

5.1. The Scope of this Report
6. Consider the Therapeutic Target for the Highest Therapeutic Outcome and Return on Investment (174 Drug Targets)
7. Emerging New Products to Established Ones: Drug Target Strategies of Cancer Drugs Affecting Angiogenesis by their Highest Stage of Development (167 Drug Target Strategies and 239 Drugs)
8. Compound Strategies at Work: Competitive Benchmarking of Cancer Drugs Affecting Angiogenesis by Compound Strategy (7 Different Compound Strategies)
9. Selecting Cancer Indications for Angiogenesis Affecting Drugs in Oncology (64 Cancer Indications)
10. Pipeline and Portfolio Planning: Competitive Benchmarking of the Angiogenesis Affecting Drug Pipeline in Oncology by Investigator (148 Investigators)
10. Disclaimer
11. Drug Index
12. Company Index

Figures: Includes 7 Figures
Tables: Includes 300 Tables
Total Number of Pages: 1227

Featured Companies:

This Report Includes the Following Companies:

3SBio
Abbott
Abiogen
Abraxis BioScience
Acceleron Pharma
Access
ACT Biotech
Actelion
Active Biotech
Adherex
Advanced Cancer Therapeutics
Advanced Life Sciences
Advantagene
Advaxis
Advenchen
Aeterna Zentaris
Affimed Therapeutics
Agennix
Aida Pharmaceuticals
Alchemia
Alethia Biotherapeutics
Allos Therapeutics
Alnylam
AlphaVax
Alseres Pharmaceuticals
Altor BioScience
Ambit Biosciences
Ambrilia Biopharma
Amgen
Amphora
Anavex Life Sciences
AngioChem
Angiogen
Angiogenex
Angstrom Pharmaceuticals
Ansaris
Antisense Pharma
Antisoma
Aphios
ApopLogic Pharmaceuticals
Apotex
Arana Therapeutics
Ariad
Arno Therapeutics
ArQule
Array BioPharma
Astellas
Astex Therapeutics
AstraZeneca
Attenuon
Austrianova
AVEO
AVI BioPharma
Bayer
Betapharma
Bio-Medisinsk Innovasjon
BioAlliance Pharma
BioAxone
Biocompatibles
Biogen Idec
Biokine Therapeutics
BioNumerik
Biosceptre
Biotecnol
BioVex
Boehringer Ingelheim
Bolder BioTechnology
Bristol-Myers Squibb
BTG
Can-Fite BioPharma
Cancer Advances
Cancer Research Technology
CDG Therapeutics
Celator Pharmaceuticals
Celecure
Celera
Celgene
Cell Genesys
Cell Therapeutics
CellCeutix
Celldex Therapeutics
Cellmid
Celsion
Celtic Pharma
Center of Molecular Immunology
Cephalon
CG Therapeutics
ChemGenex Pharmaceuticals
ChemoCentryx
Chemokine Therapeutics
China Sky One Medical
Choongwae
Circadian Technologies
CJ Corp
Clavis Pharma
Cosmo Pharmaceuticals
CSL
Cue Biotech
CuraGen
CureTech
Curis
Cyclacel
Cylene Pharmaceuticals
Cynvec
CytImmune Sciences
Cytochroma
Cytokinetics
Daewoong
Daiichi Sankyo
Dainippon Sumitomo Pharma
Dara Biosciences
Deciphera Pharmaceuticals
Dendreon
DNAVEC
Dong-A
Dyax
Dynavax Technologies
EGEN Inc
Eisai
Eli Lilly
Endocyte
Enkam Pharmaceuticals
EntreMed
Enzon
Epeius Biotechnologies
EpiCept
Etubics
Exelixis
ExonHit Therapeutics
Facet Biotech
FasTrack Pharmaceuticals
Five Prime Therapeutics
Flamel Technologies
GammaCan
Genmab
Genta
GenVec
Genzyme
Gilead Sciences
GlaxoSmithKline
GlycoGenesys
Gradalis
Green Cross
Heidelberg Pharma
Hemispherx Biopharma
Hoffmann-La Roche
Human Genome Sciences
Hy BioPharma
Ichor Medical Systems
Idera Pharmaceuticals
IkerChem
ImClone Systems
Immunocore
ImmunoGen
Immunomedics
ImmuPharma
Immutep
Incyte Corporation
Infinity Pharmaceuticals
Innate Pharma
InNexus Biotechnology
Inotek
Inovio
Insys Therapeutics
Intrexon
Introgen Therapeutics
Ipsen
ISA Pharmaceuticals
Isis Pharmaceuticals
Ivy Medical Chemicals
Jennerex Biotherapeutics
Johnson & Johnson
KAI Pharmaceuticals
Kalypsys
Karus Therapeutics
Karyon-CTT
Kiadis
Kirin Pharma
Kringle Pharma
Kyowa Hakko Kirin
Labopharm
Lee' s Pharmaceutical
Leo
LG Life Sciences
Lorus Therapeutics
MacroGenics
Mannkind
MAT Biopharma
Meda
MediGene
Medisyn Technologies
Merck & Co
Merck KGaA
Merrimack
Mersana Therapeutics
MethylGene
Micromet
Mitsubishi Tanabe Pharma
Mochida
Mojave Therapeutics
MolMed
Mologen
Morvus Technology
Nektar Therapeutics
Nerviano Medical Sciences
NewSouth Innovations
NicOx
Nippon Kayaku
Non-industrial source
Novartis
Novelix
Novogen
Nycomed Pharma
Oasmia
Oncalis
OncoGenex Pharmaceuticals
OncoMed
Onconova
OncoTherapy Science
Oncothyreon
Oncozyme Pharma
Onyvax
Orca Therapeutics
Orchestra Therapeutics
OSI Pharmaceuticals
Oxford BioMedica
OXiGENE
PanaGin
PBL Therapeutics
Pepscan Therapeutics
PepTx
Peregrine Pharmaceuticals
Pfizer
Pharmaclon
Pharmacopeia
Pharmacyclics
PharmaGap
PharmaMar
Pharmexa
Pharminox
Philogen
PhiloGene
Pierre Fabre
Piramal
Plexxikon
POZEN
Pro-Pharmaceuticals
Progen
Protein Sciences
Protherics
PTC Therapeutics
Reata Pharmaceuticals
Receptor BioLogix
Regeneron
Regulon
Rexahn
Rigel
Sanofi-Aventis
Santaris Pharma
Sareum
Scancell
SciClone Pharmaceuticals
Seattle Genetics
Semafore Pharmaceuticals
Shire
Sigma-Tau
Simcere Pharmaceuticals
Solbec Pharmaceuticals
Spear Therapeutics
Spirogen
SRI International
SuperGen
Supratek Pharma
Swedish Orphan Biovitrum
Switch Pharma
SynDevRx
Synta Pharmaceuticals
Taiho
Takeda
Talon Therapeutics
Targa Therapeutics
Targepeutics
Tau Therapeutics
Taxolog
Telik
Thallion Pharmaceuticals
The Genetics Company
Therion Biologics
ThromboGenics
Tigris Pharmaceuticals
Titan Pharmaceuticals
ToolGen
TopoTarget
Tracon Pharmaceuticals
Transgene
Trion Pharma
UCB
VaxOnco
VBL Therapeutics
Vectura
Vertex Pharmaceuticals
Vical
Wilex
VioQuest
VioQuest Pharmaceuticals
Viralytics
ViroTarg
Wyeth
Xerion
Yakult Honsha
YM BioSciences
York Pharma

ZymoGenetics

Featured Drugs:

A Shortlist of Drugs Included are:

aflibercept
AG-14699
agatolimod
aldesleukin
ALT-801
Angiozyme
apatinib
APO-866
ARQ-197
astuprotimut-r
axitinib
bardoxolone methyl
belinostat
bevacizumab
BIBF-1120
BMS-663513
bortezomib
bosentan
brivanib alaninate
capecitabine
catumaxomab
cediranib
cetuximab
cilengitide
cositecan
dasatinib
decitabine
denenicokin
dovitinib lactate
doxifluridine
EMD-273063
endostatin
entinostat
enzastaurin hydrochloride
epirubicin
everolimus
Exherin
fosbretabulin tromethamine
fresolimumab
gefitinib
glembatumumab
golnerminogene pradenovec
GT-111
GV-1001
HBP-347
histamine dihydrochloride
imatinib mesilate
IMP-321
INGN-241
interferon gamma
interferon-alpha
interferon-alpha2
interferon-alpha2a
interferon-alpha2b
interferon-beta
interleukin-2, 2nd-generation
intetumumab
IPH-1101
ipilimumab
irinotecan bead
irinotecan hydrochloride
ispinesib mesylate
JX-594
kahalalide F
L19-IL2
linifanib
LipoVIL12
MDX-1106
MetXia
MGN-1601
MGN-1703
midostaurin
MKC-1106-MT
motesanib diphosphate
oblimersen sodium
OncoVEX GM-CSF
OTS-102
P-276-00
panitumumab
patupilone
pazopanib hydrochloride
peginterferon alfa-2b
perifosine
plitidepsin
PLX-4032
raltitrexed
ramucirumab
regorafenib
retaspimycin
ridaforolimus
sagopilone
sargramostim
selumetinib
sodium stibogluconate
sorafenib tosylate
sunitinib malate
talactoferrin alfa
tegafur + uracil
tegafur + uracil + leucovorin
thymalfasin
tipifarnib
topotecan
trabedersen
tremelimumab
TS-1
vandetanib
velimogene aliplasmid
veliparib
volociximab
XL-184

YM-155

簡介
目錄
相關商品

使用指南產品及服務須知網站導覽

星期一到星期五 / 9:30am - 6:00pm
TEL: 02-2729-4219 (+886-2-2729-4219)
E-mail: tw-info@gii.co.jp

大腸癌、黑色素細胞癌、血管增生分析

Triple Analysis: Colorectal Cancer, Melanoma and Angiogenesis